Illumina, Inc. (NASDAQ:ILMN) Receives $165.95 Average Price Target from Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have received a consensus recommendation of “Moderate Buy” from the twenty research firms that are presently covering the firm, Marketbeat Ratings reports. Eight research analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $165.95.

Several equities research analysts have weighed in on ILMN shares. Robert W. Baird increased their target price on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Citigroup lowered Illumina from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $190.00 to $165.00 in a report on Wednesday, December 11th. Canaccord Genuity Group increased their price target on Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a report on Tuesday, November 5th. Royal Bank of Canada lifted their price target on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Finally, Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective for the company in a research report on Thursday, October 17th.

Illumina Stock Down 1.3 %

Shares of Illumina stock opened at $133.57 on Thursday. The business has a fifty day simple moving average of $142.59 and a 200 day simple moving average of $130.84. The stock has a market cap of $21.18 billion, a PE ratio of -13.41 and a beta of 1.11. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. Illumina has a 12 month low of $100.08 and a 12 month high of $156.66.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.33 EPS. Research analysts predict that Illumina will post 4.11 EPS for the current year.

Hedge Funds Weigh In On Illumina

A number of institutional investors have recently added to or reduced their stakes in ILMN. Industrial Alliance Investment Management Inc. acquired a new position in shares of Illumina during the 2nd quarter worth about $34,000. TD Private Client Wealth LLC increased its position in Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after buying an additional 141 shares during the last quarter. Massmutual Trust Co. FSB ADV raised its stake in Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after buying an additional 168 shares during the period. Private Trust Co. NA raised its stake in Illumina by 81.2% in the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after buying an additional 212 shares during the period. Finally, Focused Wealth Management Inc bought a new position in shares of Illumina during the 3rd quarter worth approximately $63,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.